Failure mode and bimodal restenosis of drug-coated balloon in femoropopliteal intervention

被引:7
|
作者
Huang, Hsuan-Li [1 ,2 ]
Chou, Hsin-Hua [1 ,2 ]
Chen, I-Chih [3 ]
Hsieh, Chien-An [1 ]
Jang, Shih-Jung [1 ]
Tzeng, I-Shiang [4 ]
Ko, Yu-Lin [1 ,2 ]
机构
[1] Buddhist Tzu Chi Med Fdn, Taipei Tzu Chi Hosp, Div Cardiol, Dept Internal Med, New Taipei, Taiwan
[2] Tzu Chi Univ, Sch Med, Hualien, Taiwan
[3] Tainan Municipal Hosp, Div Cardiol, Dept Internal Med, Tainan, Taiwan
[4] Buddhist Tzu Chi Med Fdn, Taipei Tzu Chi Hosp, Dept Res, New Taipei, Taiwan
关键词
Drug-coated balloon; Restenosis; Femoropopliteal; Failure mode; PACLITAXEL-ELUTING STENTS; CLINICAL-OUTCOMES; ARTERY-DISEASE; ZILVER PTX; FEMORAL-ARTERY; CLASSIFICATION; EPIDEMIOLOGY; PREVALENCE; PATTERNS; IMPACT;
D O I
10.1016/j.ijcard.2018.02.040
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Pattern of DCB restenosis and associated outcomes in facing complex femoropopliteal lesions remain uncertain. Methods: Data were retrospectively collected from dual centers in Taiwan on patients who underwent treatment with DCBs for femoropopliteal lesions between 2013 and 2016. The restenosis pattern was categorized by the index-treated length. Clinical outcomes and time to DCB restenosis were retrospectively analyzed. Cox proportional hazards model identified restenosis predictors. Results: We recruited a total of 164 patients (91 men; median age 73 years) into the final analysis. The mean lesion length was 204.0 +/- 109.2 mm. Of them, 45% total occlusions, 28% severe calcification and 15% in-stent restenosis were treated. Fifty-five patients have DCB restenosis (28 focal and 27 diffuse-occlusive patterns) over a 55-month follow-up. The median restenosis time emerged as a bimodal pattern with a significant difference between the diffuse-occlusive and focal restenosis group (225 vs. 484 days, P = 0.01). The 1-year patency rate after reintervention for DCB restenosis also was different between both restenosis group (29% vs. 65%, P = 0.017). The anticipated timing of escape for diffuse-occlusive or focal restenosis was 687 and 1068 days, respectively. Independent factorswere lesion length (P = 0.049) for diffuse-occlusive restenosis and lumen gain of the popliteal artery for focal restenosis (P = 0.034). Conclusions: This study demonstrated time to DCB failure emerged as a bimodal pattern of distribution and associations of restenosis pattern to subsequent outcomes after the repeated intervention. Exemption from late catchup restenosis required 3-year observation instead of the 1-year mark for conventional treatment. (c) 2018 Elsevier B.V. All rights reserved.
引用
收藏
页码:170 / 177
页数:8
相关论文
共 50 条
  • [1] Clinical Outcomes of Repetition of Drug-Coated Balloon for Femoropopliteal Restenosis After Drug-Coated Balloon Treatment
    Jang, Shih-Jung
    Chou, Hsin-Hua
    Juang, Jyh-Ming Jimmy
    Hsieh, Chien-An
    Duan, De-Min
    Huang, Hsuan-Li
    Ko, Yu-Lin
    CIRCULATION JOURNAL, 2017, 81 (07) : 993 - 998
  • [2] Determinants of Drug-Coated Balloon Failure in Patients Undergoing Femoropopliteal Arterial Intervention
    Krishnan, Prakash
    Farhan, Serdar
    Schneider, Peter
    Kamran, Haroon
    Iida, Osamu
    Brodmann, Marianne
    Micari, Antonio
    Sachar, Ravish
    Urasawa, Kasuki
    Scheinert, Dierk
    Ando, Kenji
    Tarricone, Arthur
    Doros, Gheorghe
    Tepe, Gunnar
    Yokoi, Hiroyoshi
    Laird, John
    Zeller, Thomas
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 80 (13) : 1241 - 1250
  • [3] Predictors of recurrent restenosis after repeat drug-coated balloon therapy for drug-coated balloon restenosis in femoropopliteal lesions: Results of the RECURRENCE study
    Yanagiuchi, Takashi
    Fukai, Kuniyoshi
    Sogabe, Koji
    Iwasaki, Yoshihiro
    Hirano, Keita
    Kato, Taku
    Yokoi, Hirokazu
    Zen, Kan
    Matoba, Satoaki
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2024, 104 (06) : 1241 - 1250
  • [4] Is Drug-Coated Balloon the Real Winner for Femoropopliteal Artery Intervention?
    Liistro, Francesco
    JACC-CARDIOVASCULAR INTERVENTIONS, 2023, 16 (13) : 1651 - 1653
  • [5] Safety and efficacy of paclitaxel drug-coated balloon in femoropopliteal in-stent restenosis
    Anantha-Narayanan, Mahesh
    Love, Keith
    Nagpal, Sameer
    Sheikh, Azfar Bilal
    Regan, Christopher J.
    Mena-Hurtado, Carlos
    EXPERT REVIEW OF MEDICAL DEVICES, 2020, 17 (06) : 533 - 539
  • [6] Clinical Impact of the Size of Drug-Coated Balloon Therapy on Restenosis Rate in Femoropopliteal Lesions
    Kurata, Naoya
    Iida, Osamu
    Takahara, Mitusyoshi
    Asai, Mitsutoshi
    Masuda, Masaharu
    Okamoto, Shin
    Ishihara, Takayuki
    Nanto, Kiyonori
    Kanda, Takashi
    Tsujimura, Takuya
    Matsuda, Yasuhiro
    Hata, Yousuke
    Mano, Toshiaki
    JOURNAL OF ENDOVASCULAR THERAPY, 2023, 30 (02) : 269 - 280
  • [7] Debulking plus drug-coated balloon angioplasty versus drug-coated balloon angioplasty alone for femoropopliteal Tosaka III in-stent restenosis lesions
    Li, Liqiang
    Tong, Zhu
    Cui, Shijun
    Guo, Lianrui
    VIDEOSURGERY AND OTHER MINIINVASIVE TECHNIQUES, 2023, 18 (01) : 166 - 172
  • [8] Diabetes mellitus and femoropopliteal in-stent restenosis: Insights from the dRug-coatEd balloon angioPlasty for femoropopliteAl In-stent Restenosis cooperation
    Voll, Felix
    Wolf, Florian
    Ingwersen, Maja
    Kinstner, Christian M.
    Kufner, Sebastian
    Ibrahim, Tareq
    Ott, Ilka
    Krankenberg, Hans
    Fusaro, Massimiliano
    Cassese, Salvatore
    VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE, 2022, 51 (04) : 247 - 255
  • [9] Drug-Coated Balloon for the Treatment of Femoropopliteal Tosaka Class III In-stent Restenosis Lesions
    Zhang, Bihui
    Niu, Guochen
    Yan, Ziguang
    Zou, Yinghua
    Tong, Xiaoqiang
    Yang, Min
    FRONTIERS IN SURGERY, 2021, 7
  • [10] Drug-coated balloon angioplasty for in-stent restenosis of femoropopliteal arteries: a meta-analysis
    Cassese, Salvatore
    Ndrepepa, Gjin
    Kufner, Sebastian
    Byrne, Robert A.
    Giacoppo, Daniele
    Ott, Ilka
    Laugwitz, Karl-Ludwig
    Schunker, Heribert
    Kastrati, Adnan
    Fusaro, Massimiliano
    EUROINTERVENTION, 2017, 13 (04) : 483 - 489